Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

被引：0
|
作者：
N B Leighl
J Bennouna
J Yi
N Moore
J Hambleton
H Hurwitz
机构：
[1] Princess Margaret Hospital,Division of Medical Oncology
[2] Centre René Gauducheau,Division of Medical Oncology
[3] Genentech,Division of Medical Oncology
[4] Inc.,undefined
[5] Hoffman-La Roche,undefined
[6] Inc.,undefined
[7] Duke University School of Medicine,undefined
来源：
British Journal of Cancer | 2011年 / 104卷
关键词：
bevacizumab; non-small cell lung cancer; colorectal cancer; anticoagulation; haemorrhage; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：413 / 418
页数：5
相关论文
共 50 条
  • [21] Improved survival for patients with metastatic breast cancer treated with high dose chemotherapy compared with matched controls who received conventional treatment
    Donnellan, P
    Dillon, P
    Hoey, S
    Baker, A
    Smith, M
    Cameron, D
    Leonard, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S330 - S330
  • [22] Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study
    Korach, Jacob
    Colombo, Nicoletta
    Mendiola, Cesar
    Selle, Frederic
    Dolado, Ignacio
    Donica, Margarita
    Oza, Amit M.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (04) : 786 - 793
  • [23] Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study
    Maeda, Isseki
    Inoue, Shinichiro
    Uemura, Keiichi
    Tanimukai, Hitoshi
    Hatano, Yutaka
    Yokomichi, Naosuke
    Amano, Koji
    Tagami, Keita
    Yoshiuchi, Kazuhiro
    Ogawa, Asao
    Iwase, Satoru
    JOURNAL OF PALLIATIVE MEDICINE, 2021, 24 (06) : 914 - 918
  • [24] Step down to 6 months of prophylactic-dose low molecular weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): A pilot study
    Popov, Jesse
    Coelho, Suellen
    Carrier, Marc
    Sperlich, Catherine
    Solymoss, Susan
    Routhier, Nathalie
    Shivakumar, Sudeep
    Aibibula, Wusiman
    Kahn, Susan R.
    Tagalakis, Vicky
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (08) : 1868 - 1874
  • [25] Tolerance of full-dose sorafenib (S) combined with irinotecan (I; weekly, two on, one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC)
    Dasari, A.
    Rudek, M. A.
    Arcaroli, J.
    Powell, R. W.
    Carducci, M. A.
    Laheru, D.
    Wright, J. J.
    Hidalgo, M.
    Messersmith, W. A.
    Azad, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [26] PATIENT-REPORTED OUTCOMES IN ELDERLY BEVACIZUMAB-TREATED PRIMARY OVARIAN CANCER PATIENTS: OTILIA STUDY ON BEHALF OF THE NORTH-EASTERN GERMAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY (NOGGO)
    Sehouli, J.
    Wimberger, P.
    Oskay-Oezcelik, G.
    Jungberg, P.
    Meinerz, W.
    Wegenaer, A.
    Reichert, D.
    Mustea, A.
    Janssen, J.
    Klawitter, S.
    Keller, M.
    Richter, R.
    Harde, J.
    Mueller, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 29 - 30
  • [27] Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy
    Sra, Steven
    Tan, Mary K.
    Mehta, Shamir R.
    Fisher, Harold N.
    Dery, Jean-Pierre
    Welsh, Robert C.
    Eisenberg, Mark J.
    Overgaard, Christopher B.
    Rose, Barry F.
    Della Siega, Anthony J.
    Cheema, Asim N.
    Wong, Brian Y. L.
    Henderson, Mark A.
    Lutchmedial, Sohrab
    Lavi, Shahar
    Goodman, Shaun G.
    Yan, Andrew T.
    AMERICAN HEART JOURNAL, 2016, 180 : 82 - 89
  • [28] Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
    Garrett, C. R.
    Siu, L. L.
    El-Khoueiry, A.
    Buter, J.
    Rocha-Lima, C. M.
    Marshall, J.
    LoRusso, P.
    Major, P.
    Chemidlin, J.
    Mokliatchouk, O.
    Velasquez, L.
    Hayes, W.
    Feltquate, D.
    Syed, S.
    Ford, S.
    Kollia, G.
    Galbraith, S.
    Nuyten, D. S. A.
    BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 44 - 52
  • [29] Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
    C R Garrett
    L L Siu
    A El-Khoueiry
    J Buter
    C M Rocha-Lima
    J Marshall
    P LoRusso
    P Major
    J Chemidlin
    O Mokliatchouk
    L Velasquez
    W Hayes
    D Feltquate
    S Syed
    S Ford
    G Kollia
    S Galbraith
    D S A Nuyten
    British Journal of Cancer, 2011, 105 : 44 - 52
  • [30] Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC).
    Sandler, A. B.
    Johnson, D. H.
    Brahmer, J.
    Schiller, J. H.
    Ostland, M.
    Gray, R.
    Tran, S.
    Dimery, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 381S - 381S
12345